YABAO PHARM.CORP(SH:600351) 智通财经网·2025-10-13 08:57Core Viewpoint - Company YaBao Pharmaceutical (600351.SH) has received approval from the National Medical Products Administration for the registration of its product, Sitagliptin Metformin Extended-Release Tablets, which is intended for adult patients with type 2 diabetes [1] Group 1: Product Approval - YaBao's wholly-owned subsidiary, Beijing YaBao Biopharmaceutical Co., Ltd., has been granted the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets (Certificate No: 2025S03027) [1] - The product is designed for adults currently undergoing treatment with a combination of Sitagliptin and Metformin Extended-Release Tablets [1] Group 2: Market Context - Sitagliptin Metformin Extended-Release Tablets were developed by Merck Sharp & Dohme and were approved for sale in the United States in 2012 under the brand name JANUMETXR® [1] - According to data from Minet, the total sales amount for Sitagliptin Metformin Tablets (I), Sitagliptin Metformin Tablets (II), and Sitagliptin Metformin Extended-Release Tablets in China is approximately 921 million RMB for 2024 [1] - Of this total, sales in public hospitals account for 721 million RMB, while retail pharmacies contribute 200 million RMB [1]